Jasper Therapeutics, Inc. (JSPRW) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Currency In USD
Address
2200 Bridge Pkwy
Redwood City, DE 94065
United States of America (the)
Phone
650 549 1400
Sector
Healthcare
Industry
Biotechnology
Employees
64
First IPO Date
January 10, 2020
| Name | Title | Pay | Year Born |
| Jeetinder Singh Mahal | President, COO, CEO & Director | 610,050 | 1973 |
| Judith Anne Shizuru | Co-Founder, Member of Scientific Advisory Board & Director | 46,300 | 1957 |
| Thomas G. Wiggans | Executive Chairman | 70,000 | 1952 |
| Herbert C. Cross | Chief Financial Officer & Corporate Secretary | 603,925 | 1972 |
| Luca Di Noto | Senior Vice President of Technical Operations | 0 | N/A |
| Matthew Ford | Senior Vice President of Human Resources | 0 | N/A |
| Patricia Carlos | Senior Vice President of Regulatory Affairs & Quality | 0 | N/A |
| Alex Gray | Head of Investor Relations | 0 | N/A |
| Daniel C. Adelman | Acting Chief Medical Officer, Member of Scientific Advisory Board & Senior Clinical Advisor | 0 | 1957 |
Jasper Therapeutics, Inc. is a biotechnology company in the clinical development phase, dedicated to creating and advancing therapeutic agents for both hematopoietic stem cell transplantation and gene therapies. Their strategic focus encompasses the development and eventual commercialization of treatments for a variety of conditions. These include chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and the formulation of innovative preparatory treatments (conditioning regimens) for stem cell transplantation and ex-vivo gene therapy – a method where cells are genetically modified outside the body before being transplanted back into a patient. The company's lead investigational product is briquilimab, a novel therapeutic antibody undergoing clinical trials. Briquilimab functions by clearing hematopoietic stem cells from a patient's bone marrow before they receive an allogeneic stem cell or stem cell gene therapy. In addition, Jasper Therapeutics is engineering specialized hematopoietic stem cell product candidates designed to overcome critical limitations often encountered with allogeneic and autologous gene-edited stem cell grafts. The company's corporate headquarters are located in Redwood City, California.